Literature DB >> 17040578

Molecular basis of inherited skin-blistering disorders, and therapeutic implications.

Monique Aumailley1, Cristina Has, Lucy Tunggal, Leena Bruckner-Tuderman.   

Abstract

Epidermolysis bullosa (EB) and associated skin-fragility syndromes are a group of inherited skin diseases characterised by trauma-induced blistering of the skin and mucous membranes. Mutations in at least 14 distinct genes encoding molecular components of the epidermis or the dermal-epidermal junction (DEJ) can cause blistering skin diseases that differ by clinical presentation and severity of the symptoms. Despite great advances in discerning the genetic basis of this group of diseases, the molecular pathways leading to symptoms are not yet fully understood. Unravelling these pathways by molecular analysis of the structure and in vitro assessment of functional properties of the human proteins involved, combined with genetic models in lower organisms, should pave the way for specific cures for inherited skin fragility.

Entities:  

Mesh:

Year:  2006        PMID: 17040578     DOI: 10.1017/S1462399406000123

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  24 in total

Review 1.  Integrins and extracellular matrix in mechanotransduction.

Authors:  Martin Alexander Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-11-17       Impact factor: 10.005

Review 2.  Basement membranes in skin: unique matrix structures with diverse functions?

Authors:  Dirk Breitkreutz; Nicolae Mirancea; Roswitha Nischt
Journal:  Histochem Cell Biol       Date:  2009-03-31       Impact factor: 4.304

3.  Can type VII collagen injections cure dystrophic epidermolysis bullosa?

Authors:  Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-01       Impact factor: 11.454

4.  Supramolecular interactions in the dermo-epidermal junction zone: anchoring fibril-collagen VII tightly binds to banded collagen fibrils.

Authors:  Daniela Villone; Anja Fritsch; Manuel Koch; Leena Bruckner-Tuderman; Uwe Hansen; Peter Bruckner
Journal:  J Biol Chem       Date:  2008-07-03       Impact factor: 5.157

5.  Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.

Authors:  Johannes S Kern; Stefan Loeckermann; Anja Fritsch; Ingrid Hausser; Wera Roth; Thomas M Magin; Claudia Mack; Marcel L Müller; Oliver Paul; Patrick Ruther; Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

6.  Laminin-332 coordinates mechanotransduction and growth cone bifurcation in sensory neurons.

Authors:  Li-Yang Chiang; Kate Poole; Beatriz E Oliveira; Neuza Duarte; Yinth Andrea Bernal Sierra; Leena Bruckner-Tuderman; Manuel Koch; Jing Hu; Gary R Lewin
Journal:  Nat Neurosci       Date:  2011-07-03       Impact factor: 24.884

7.  Highly efficient zinc-finger nuclease-mediated disruption of an eGFP transgene in keratinocyte stem cells without impairment of stem cell properties.

Authors:  Thorsten Höher; Lee Wallace; Kafaitullah Khan; Toni Cathomen; Julia Reichelt
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

8.  High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa.

Authors:  Tobias Kühl; Markus Mezger; Ingrid Hausser; Rupert Handgretinger; Leena Bruckner-Tuderman; Alexander Nyström
Journal:  Mol Ther       Date:  2015-04-10       Impact factor: 11.454

Review 9.  Anaesthetic management of children with epidermolysis bullosa.

Authors:  L Bowen; M T Burtonwood
Journal:  BJA Educ       Date:  2017-11-28

10.  A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy.

Authors:  Anja Fritsch; Stefan Loeckermann; Johannes S Kern; Attila Braun; Michael R Bösl; Thorsten A Bley; Hauke Schumann; Dominik von Elverfeldt; Dominik Paul; Miriam Erlacher; Dirk Berens von Rautenfeld; Ingrid Hausser; Reinhard Fässler; Leena Bruckner-Tuderman
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.